Geron Projects Strong RYTELO Sales of $220-240M, Imetelstat Data Shows Durable Efficacy
GERN sits 50% above its 52-week low of $1.04.
Summary
Geron Corporation reported its first-quarter 2026 financial results, including $51.8 million in RYTELO net product revenue, and provided new, positive full-year 2026 revenue guidance for RYTELO of $220-240 million. The company also highlighted durable transfusion independence data for its telomerase inhibitor, imetelstat, in lower-risk MDS. This guidance and clinical update are significant for the company, reinforcing the commercial potential of RYTELO and the therapeutic value of imetelstat. While the Q1 revenue was previously reported, the new guidance and clinical data provide fresh, material information for investors. Traders will be watching for further updates on the company's expansion into relapsed/refractory myelofibrosis and pending Phase 3 results.
At the time of this announcement, GERN was trading at $1.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.04 to $2.01. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.